Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
-
BUSINESS Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
-
REGULATORY Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
-
REGULATORY MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
-
TRENDS Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
REGULATORY Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
-
REGULATORY Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
-
REGULATORY (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
-
REGULATORY 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
-
REGULATORY Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
-
BUSINESS Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
-
BUSINESS Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
-
BUSINESS Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
-
BUSINESS Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
-
BUSINESS Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
-
BUSINESS Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
-
REGULATORY LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
-
BUSINESS Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
-
BUSINESS 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
-
REGULATORY “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…